Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels

Abstract In the randomized, phase 3, MDS-005 study (NCT01029262), lenalidomide-induced red blood cell transfusion independence (RBC-TI) in 27% of transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes (MDS) ineligible for or refractory to erythropoiesis-stimulating agents. To determine the influence of erythropoietin (EPO) level on response, 155 patients treated with lenalidomide in MDS-005 were categorized into four groups by baseline EPO level. The EPO >500 mU/mL group had higher RBC transfusion burden and the lowest proportion of patients with ring sideroblasts ≥15% versus lower EPO groups. Achievement of RBC-TI ≥8 weeks inversely correlated with EPO level, ranging from 42.5 to 15.5%. EPO level did not affect erythroid hematologic improvement response (36.2–44.4%). This analysis suggests patients with lower EPO levels experience the strongest benefit from lenalidomide. Although meaningful improvements were observed in some patients with EPO level >500 mU/mL, new treatments are needed for this population.

[1]  M. Cazzola,et al.  The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions , 2018, Blood.

[2]  K. Götze,et al.  A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS , 2018, Leukemia.

[3]  K. Götze,et al.  Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. , 2017, The Lancet. Oncology.

[4]  U. Platzbecker,et al.  Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors. , 2017, Seminars in hematology.

[5]  A. List,et al.  Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. , 2017, Seminars in hematology.

[6]  M. Delforge,et al.  A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes , 2017, Leukemia.

[7]  A. Stamatoullas,et al.  Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  V. Santini.  Treatment of low-risk myelodysplastic syndromes. , 2016, Hematology. American Society of Hematology. Education Program.

[9]  G. Mufti,et al.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Tavernier,et al.  Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. , 2016, Cancer research.

[11]  A. Stamatoullas,et al.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion , 2016, Leukemia.

[12]  S. Carr,et al.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.

[13]  Sheng Wei,et al.  Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors , 2014, PloS one.

[14]  M. Cazzola,et al.  Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.

[15]  A. Stamatoullas,et al.  Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents , 2013, Leukemia.

[16]  J. Lancet,et al.  Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. , 2012, Blood.

[17]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[18]  A. Bosi,et al.  Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients , 2012, Clinical Cancer Research.

[19]  G. Fuhler,et al.  Erythropoietin Receptor Signaling Is Membrane Raft Dependent , 2012, PloS one.

[20]  Harvey F Lodish,et al.  From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. , 2011, Blood.

[21]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[22]  M. Cazzola,et al.  Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS) , 2011, Haematologica.

[23]  A. Stamatoullas,et al.  Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. , 2010, Leukemia research.

[24]  A. Warren,et al.  A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q− syndrome , 2009, Nature Medicine.

[25]  P. Nguyen,et al.  Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.

[26]  H. Dombret,et al.  Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.

[27]  H. Dombret,et al.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.

[28]  M. Sekharam,et al.  Lenalidomide (CC-5013; Revlimid®) Promotes Erythropoiesis in Myelodysplastic Syndromes (MDS) by CD45 Protein Tyrosine Phosphatase (PTP) Inhibition. , 2006 .

[29]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[30]  A. Kasprzyk,et al.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.

[31]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[32]  I. Dybedal,et al.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. , 1998, Blood.

[33]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.